cancer

Novartis CEO Vas Narasimhan is raising the bar on second-gen cancer drug studies
Novartis CEO Vas Narasimhan is raising the bar on second-gen cancer drug studies
Endpoints
Novartis
cancer
Pharma CEOs
Vas Narasimhan
Flag link:
We're about to get some key lung cancer data — and it could affect how hundreds of thousands of cancer patients are treated
We're about to get some key lung cancer data — and it could affect how hundreds of thousands of cancer patients are treated
San Francisco Gate, CA
lung cancer
cancer
Merck
Roche
Bristol-Myers Squibb
AACR
non-small cell lung cancer
Flag link:
Nektar begins Phase 1/2 Clinical Study to Evaluate Combination of TLR Agonist NKTR-262 With CD122-Biased Agonist NKTR-214 in Patients With Advanced Solid Tumors
Nektar begins Phase 1/2 Clinical Study to Evaluate Combination of TLR Agonist NKTR-262 With CD122-Biased Agonist NKTR-214 in Patients With Advanced Solid Tumors
CP Wire
Nektar Therapeutics
NKTR-214
NKTR-262
cancer
solid tumors
Flag link:
Novartis offloads failed cancer drug to Oncology Venture
Novartis offloads failed cancer drug to Oncology Venture
Fierce Biotech
Novartis
Oncology Venture
dovitinib
kidney cancer
cancer
Flag link:
Physician payments linked to scripts for cancer drugs from Novartis, Pfizer and more: study
Physician payments linked to scripts for cancer drugs from Novartis, Pfizer and more: study
Fierce Pharma
physician payments
Novartis
Pfizer
Bayer
Bristol-Myers Squibb
cancer
Flag link:
Visiongate Announces Next Step in Commercialization of Cancer Detection Platform
Visiongate Announces Next Step in Commercialization of Cancer Detection Platform
CP Wire
VisionGate
cancer
diagnostics
Cell-CT
LuCED Lung Test
lung cancer
Flag link:
J&J loses trial over claims linking cancer to asbestos in talc
J&J loses trial over claims linking cancer to asbestos in talc
Yahoo/Reuters
JNJ
cancer
Flag link:
In salvage effort, Sellas cherry picks some positive mid-stage cancer vaccine data
In salvage effort, Sellas cherry picks some positive mid-stage cancer vaccine data
Endpoints
Sellas
Galena Biopharma
NeuVax
vaccines
cancer
cancer vaccines
Flag link:
Compugen, AstraZeneca unit in cancer drug development deal
Compugen, AstraZeneca unit in cancer drug development deal
Yahoo/Reuters
AstraZeneca
CompuGen
drug development
MedImmune
cancer
Flag link:
Two Harvard Biotech Entrepreneurs Are Creating The "Trojan Horse" Of Cancer Treatment
Two Harvard Biotech Entrepreneurs Are Creating The "Trojan Horse" Of Cancer Treatment
Forbes
biotech
cancer
Flag link:
China's Aim to Remove Cancer Drug Taxes May Boost Pfizer, Glaxo
China's Aim to Remove Cancer Drug Taxes May Boost Pfizer, Glaxo
Bloomberg
China
Pfizer
GSK
cancer
taxes
Flag link:
Cotinga Pharmaceuticals Provides Update on COTI-2 PhI Clinical Programs
Cotinga Pharmaceuticals Provides Update on COTI-2 PhI Clinical Programs
CP Wire
Cotinga Pharmaceuticals
COTI-2
cancer
clinical trials
Flag link:
How Pfizer Plans to Move Into the Big Leagues for Cancer Treatment
How Pfizer Plans to Move Into the Big Leagues for Cancer Treatment
Motley Fool
cancer
oncology
Pfizer
Ibrance
breast cancer
Xtandi
prostate cancer
Bavencio
bladder cancer
Merkel cell carcinoma
lorlatinib
metastatic non-small cell lung cancer
talazoparib
metastatic breast cancer
Flag link:
MasSpec Pen Wins Award In Health, Med, Biotech Category at SXSW
MasSpec Pen Wins Award In Health, Med, Biotech Category at SXSW
CP Wire
MasSpec Pen
devices
biotech
cancer surgery
cancer
SXSW
Flag link:
FDA approves new dosing for Bristol-Myers Squibb's Opdivo
FDA approves new dosing for Bristol-Myers Squibb's Opdivo
Yahoo/Reuters
FDA
Bristol-Myers Squibb
Opdivo
dosing
cancer
melanoma
Flag link:
[video]Here’s Why Gilead Sciences' Jump Into Gene Editing Is Important
[video]Here’s Why Gilead Sciences' Jump Into Gene Editing Is Important
Motley Fool
Gilead Sciencs
gene editing
Sangamo Therapeutics
cancer
Flag link:
Quentis Nets $48M For Cancer Drugs, Building Buzz For NY Bio Startups
Quentis Nets $48M For Cancer Drugs, Building Buzz For NY Bio Startups
Xconomy
Quentis
biotech
startups
cancer
NYC
Flag link:
Merck to buy virus-based cancer drug firm Viralytics for $394 million
Merck to buy virus-based cancer drug firm Viralytics for $394 million
Reuters
Merck
Viralytics
M&A
cancer
Flag link:
Bristol-Myers To Pay Largest Fee In Biotech History For Nektar Cancer Drug
Bristol-Myers To Pay Largest Fee In Biotech History For Nektar Cancer Drug
Forbes
Bristol-Myers Squibb
Nektar Therapeutics
NKTR-214
cancer
Flag link:
AstraZeneca's Lynparza Now 'King' Of Its Class — Triumphing Over Tesaro
AstraZeneca's Lynparza Now 'King' Of Its Class — Triumphing Over Tesaro
Investors Business Daily
AstraZeneca
Lynparza
Tesaro
cancer
Rubraca
Clovis Oncology
Flag link:

Pages